seminar on nephritis, nephrotic syndrome,bladder cancer
DESCRIPTION
nephritis,nephrotic syndrome and CA bladderTRANSCRIPT
Page 1
Seminar on nephritis, nephrotic
syndrome,bladder cancer
Presented by:Ligi Xavier1 yr MSc nursing
Page 2
Nephritis
Nephritis is inflammation of the nephrons in the kidneysSubtypes
•By main location of inflammation•By cause
Page 3
Interstitial nephritis
• Interstitial nephritis is a kidney disorder in which the spaces between the kidney tubules become swollen (inflamed). The inflammation can affect the kidneys' function, including their ability to filter waste.
Page 4
Causes
• Allergic reaction to a drug (acute interstitial allergic nephritis)
• Analgesic nephropathy• Long-term use of medications such as
acetaminophen (Tylenol), aspirin, and nonsteroidal anti-inflammatory drugs (NSAIDS). This is called analgesic nephropathy
• Side effect of certain antibiotics (penicillin, ampicillin, methicillin, sulfonamide medications, and others)
• Side effect of medications such as furosemide, and thiazide diuretics
Page 5
Symptoms
:• Blood in the urine• Fever• Increased or decreased urine output • Mental status changes (drowsiness, confusion,
coma)• Nausea, vomiting • Rash• Swelling of the body, any area• Weight gain (from retaining fluid)
Page 6
Investigations
• Arterial blood gases• Blood chemistry• BUN and blood creatinine levels• Complete blood count• Kidney biopsy• Urinalysis• Urine osmolality
Page 7
Treatment
• Treatment focuses on the cause of the problem. Avoiding medications that lead to this condition may relieve the symptoms quickly.
• Limiting salt and fluid in the diet can improve swelling and high blood pressure. Limiting protein in the diet can help control the buildup of waste products in the blood (azotemia) that can lead to symptoms of acute kidney failure.
• If dialysis is necessary, it usually is required for only a short time.
• Corticosteroids or anti-inflammatory medications can help in some cases
Page 8
Glomerulonephritis
• Glomerulonephritis is inflammation of the glomeruli. Also called glomerular disease, glomerulonephritis can be acute , a sudden attack of inflammation or chronic ,coming on gradually.
Page 9
Types
• Thin Basement Membrane Disease• Acute Nephritic Syndromes• Non Proliferative
– Minimal change GN also known as Minimal Change Disease
– Focal Segmental Glomerulosclerosis (FSGS)
– Membranous glomerulonephritis
Page 10
Membraneous glomerulonephritis
Page 11
Proliferative
• IgA nephropathy (Berger's disease)• Post-infectious• Membranoproliferative/
mesangiocapillary GN• Rapidly progressive glomerulonephritis• Acute glomerulonephritis• Chronic
Page 12
Page 13
RPGN
Page 14
Causes
• Infections – Post-streptococcal glomerulonephritis– Bacterial endocarditis. – Viral infections.
Immune diseases
Vasculitis
Page 15
Pathophysiology
Antigen
Antigen – antibody product
Leukocyte infitration of glomerulus
Thikening glomerular filtration membrane
Scarring and loss of glomerular filtration membrane
Decreased GFR
Page 16
Signs and symptoms
• primary presenting features are hematuria,edema,azotemia(concentration of nitrogenous wasteproducts in the blood),proteinuria
• Pink or cola-colored urine from red blood cells in your urine (hematuria)
• Foamy urine due to excess protein (proteinuria,<3g/day)
• High blood pressure (hypertension)
Page 17
Cntd………….
• Fluid retention (edema) with swelling evident in your face, hands, feet and abdomen
• Fatigue from anemia or kidney failure• Hypoalbunemia,hyperlipidemia,fatty casts in urine• Blood urea nitrogen, creatine level may increase
as urine output decreases.• In severe conditions• -headache, malaise, flank pain,dyspnea,
cardiomegaly,pulmonary edema, neurological manifestations also occur.
Page 18
Diagnostic studies
• History and physical examination • Laboratory studies• Urinalysis;reveal the presence of erythrocytes.• CBC with WBC differencial• BUN, creatine,albumin• Complement levels and ASO titre:the finding of
decreased complement components (c3 and CH50) indicates immune mediated response.
• Renal biopsy
Page 19
Medical Management
• Antibiotic Penicillin is the choice. Corticosteroids and immunosuppressive agents
• Dietary protein ,sodiums restricted.• Loop diuretics and antihypertensives to
control hypertension• Bedrest
Page 20
Chronic glomerulonephritis
• Chronic glomerulonephritis sometimes develops after a bout of acute glomerulonephritis. It reflects the end stage of glomerular inflammatory disease. One of the inherited cause Alport syndrome, may also involve hearing or vision impairment
Page 21
Pathophysiology
• Chronic glomerulonephritis may occur due to repeated episodes of acute glomerulonephritis, hypertensive nephrosclerosis,hyperlipidemia,glomerular sclerosis, chronic tubulointerstitial disease and amyloidosis.secondary diseases lupus nephritis,Good pastures syndrome. Kidneys are reduced to as little as one fifthof normal size (consisting largely of fibrous tissue).the cortex layer shrinks to 1-2mmin thickness or less.bands of scar tissue makes the surface of kidney irregular.glomeruli and tubules become scarred, and artery become thickened. The result is severe glomerular damage can result in ESRD.
Page 22
Clinical manifestations
• BUN and creatinine values are increased• Sudden severe nosebleed, stroke, • Peripheral and periorbital edema• loss of weight• ocular findings:retinal hemorrhage, papilledema• cardiomegaly,signs of heart failure• peripheral neuropathy• in later stages,pericarditis, pericardial friction rub
Page 23
Assessment and diagnostic findings
• Urine test• Blood tests• Imaging tests• Kidney biopsy.
Page 24
Complications
• Acute kidney failure. • Chronic kidney failure• High blood pressure• Nephrotic syndrome• Hypertensive encephalopathy• Heart failure• Pulmonary edema
Page 25
Treatment for an underlying cause
• Strep or other bacterial infection. • Lupus or vasculitis• IgA nephropathy• Goodpasture's syndrome.
Page 26
Nephrotic syndrome(nephrosis)
• Results when the glomerulus is excessively permeable to plasma protein,causing proteinuria that leads to low plasma albumin and tissue edema
• Nephrotic syndrome can affect all age groups. In children, it is most common between ages 2 and 6. This disorder occurs slightly more often in males than females.
Page 27
Causes
• Primary glomerular disease– Membraneousproliferative glomerulonephritis– Primary nephritic syndrome– Focal glomerulonephritis– Inherited nephritic diseases
• External causes– SLE– Diabetes mellitus– Amyloidosis
Page 28
• Neoplasms– Hodgkin’s lymphoma– Solid tumoprs of lung,colon, stomach, breast,– Leukemias
• Infections– Bacterial:streptococcal, syphilis– Viral:hepatitis,HIV– Protozoal: malaria
Page 29
• Allergens• Drugs
– Penicillamine– NSAIDS– Captopril
Page 30
Pathophysiology
Damaged glomerular capillary membrane
Loss of plasma protein
Hypoalbuminemia
Decreased oncotic ressure
Generalised edema
Activation of RAAS
Sodium retension
edema
Page 31
Clinical manifestations
• It comprises of cluster of clinical findings• Marked increase in protein• Hypoalbuminemia• Edema• Hyper lipidemia• Other symptoms include:• Foamy appearance of the urine• Poor appetite• Weight gain (unintentional) from fluid retention
Page 32
Diagnostic measures
• Proteinuria: exceeding 3.5g/day is the hall mark of the diagnosis of nephritic syndrome.
• Albumin blood test• Blood chemistry tests such as
basic metabolic panel or comprehensive metabolic panel
• Blood urea nitrogen (BUN)• Creatinine - blood test• Creatinine clearance - urine test• Urinalysis
Page 33
Contd……..
• Creatinine clearance - urine test• Urinalysis
• Fats are often also present in the urine. Blood cholesterol and triglyceride levels may be high.
Page 34
Treatment
• Keep blood pressure at or below 130/80 mmHg to delay kidney damage. Angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) are the medicines most often used. ACE inhibitors may also help decrease the amount of protein lost in the urine.
• corticosteroids • Antineoplastic agents (cyclophosphamide),
immunosuppressants (azathioprine,chlorambucil, cyclosporine)
Page 35
• Treat high cholesterol to reduce the risk of heart and blood vessel problems. A low-fat, low-cholesterol diet is usually not very helpful for people with nephrotic syndrome. Medications to reduce cholesterol and triglycerides (usually statins) may be needed.
• Low-protein diets may be helpful. Your health care provider may suggest eating a moderate-protein diet (0.5-0.6 gram of protein per kilogram of body weight per day).
• vitamin D supplements if nephrotic syndrome is long-term and not responding to treatment.
• Blood thinners may be needed to treat or prevent blood clots.• Diuretics for severe edema
Page 36
Complications
• Acute kidney failure• Atherosclerosis and related heart diseases• Chronic kidney disease• Fluid overload, congestive heart failure,
pulmonary edema• Infections, including pneumococcal pneumonia• Malnutrition• Renal vein thrombosis• Pulmonary emboli
Page 37
Bladder cancer
• It is more common in people between the ages of 50 and 70yrs. it affects more men than women(4:1)
Page 38
Types
• Transitional cell bladder cancer• Non muscle invasive (superficial)
bladder cancer• Invasive bladder cancer
– Squamous cell bladder cancer– Adenocarcinoma of the bladder– cell cancer of the bladder
Page 39
Causes of Cancer of the Bladder
• smoking - is 2-6 times greater in smokers than in nonsmokers.
• Chemical exposure • textile workers, Dry cleaners• Dental workers• Physicians• Barbers,dye, leather, and rubber workers,
plumbing, autowork, painters
Page 40
• Race - Caucasians have twice as high a risk of developing this cancer as people of African descent; Asians have the lowest risk
• Gender - men have a 2 to 3 times higher risk than women of developing bladder cancer
• haematobium infection causes most cases of bladder SCC
• Age - most cases of bladder cancer are diagnosed in people over the age of 40 years
• previous use of certain chemotherapy medications, such as cyclophosphamide(often used in breast cancer and lymphoma treatment), can significantly increase the risk of later developing bladder cancer
Page 41
• Cancers arising from prostate,colon,rectum• Radiation treatment of the pelvis• Spinal cord injuries requiring long-term
indwelling catheters - A 16- to 20-fold increase in the risk of developing SCC of the bladder
• Previous radiation to the pelvic area• Family or personal history of bladder cancer• Schistosomiasis :In many developing countries
Page 42
Clinical features
• blood in the urine (most common)• pain or burning sensation while urinating• a feeling of urgency or needing to urinate
immediately• the feeling of not having emptied the
bladder completely after urinating• pain in the lower back
Page 43
Irritative bladder symptoms
• such as dysuria, urgency, or frequency of urination occur in 20-30% of patients with bladder cancer. Although irritative symptoms may be related to more advanced muscle-invasive disease, carcinoma in situ (CIS) is the more likely cause. Patients with advanced disease can present with pelvic or bony pain, lower-extremity edema from iliac vessel compression, or flank pain from ureteral obstruction.
Page 44
Diagnostic measures
• Urine studies include the following:• Urinalysis with microscopy• Urine culture to rule out infection, if
suspected• Voided urinary cytology• Urinary tumor marker testing
Page 45
Cystoscopy
• Cystoscopy in patients with CIS may reveal a characteristic red, velvety appearance that resembles an area of inflammation. In some cases, however, CIS is not visible on gross inspection
Page 46
Imaging studies
• Computed Tomography Scanning• Intravenous Pyelography• Renal Ultrasonography• Bone scans determine if the cancer has
spread to the bones.• Chest X-rays show if the cancer has
spread to the lungs.
Page 47
• Other tests• Complete Blood Count and Chemistry
Panel
Page 48
Staging
• The following is the TNM staging system for bladder cancer:• CIS - Carcinoma in situ, high-grade dysplasia, confined to
the epithelium• Ta - Papillary tumor confined to the epithelium• T1 - Tumor invasion into the lamina propria• T2 - Tumor invasion into the muscularis propria• T3 - Tumor involvement of the perivesical fat• T4 - Tumor involvement of adjacent organs such as the
prostate, rectum, or pelvic sidewall• N+ - Lymph node metastasis• M+ - Metastasis
Page 49
Management
• Surgical therapy– Trans urethral resection with fulgration– Laser photo coagulation– Open loop resection with fulgration– Cystectomy– Urinary diversion
Page 50
Trans urethral resection with fulgration
• Used for the diagnosis and treatment of superficial lesions with low recurrence rate. Also used to control the bleeding.
Page 51
Laser photo coagulation
• Used to teat superficial bladder cancer
Page 52
Open loop resection with fulgration
• it is used for the control of bleeding, for large superficial tumors and for multiple lesions.
Page 53
cystectomy
• Cystectomy is surgery to remove the bladder.– Partial cystectomy removes only part of the
bladder. It is used to treat cancer that has invaded the bladder wall in just one area.
– Simple cystectomy removes all of the bladder.– Radical cystectomy removes all of the bladder
as well as nearby lymph nodes, part of the urethra, and nearby organs that may contain cancer.
Page 54
Urinary diversion
• Urinary diversion is surgery that makes a new way for your body to store urine. This can be done with a pouch created inside your body from part of your intestines, called a continent reservoir.
• After cystectomy is performed, a urinary diversion must be created from an intestinal segment. Diversions can be incontinent(cutaneous) and continent.
Page 55
Cutaneous urinary diversions
• A. Conventional ileal conduit• B.Cutaneous ureterostomy• C.Vesicostomy• D.Nephrostomy
Page 56
Ileal conduit
Page 57
Cutaneous ureterostomy
Page 58
Nephrostomy
Page 59
Continent urinary diversions
• A.Indiana pouch • B.Continent ileal urinary
diversions(Kock pouch• C.Charleston pouch• D.Ureterosigmoidostomy
Page 60
Indiana pouch
Page 61
Kock pouch
Page 62
Ureterosigmoidostomy
Page 63
Other urinary diversion procedures
• Camey procedure, uses a portion of the ileumas a bladder substitute. In this procedure, the isolated ileum serves as the reservoir for urine. It is anastomosed directly to theporion of the remaining urethra after cystectomy.this procedure permits emptying of the the bladder through the urethra. However , the camay procedure applies only to men because the entireurethra is removed when a cystectomy is performed for women
Page 64
Orthotopic neobladder
• : is the constructions of a new bladder in the new anatomic positions of the bladder; with discharge of urine through the urethra. The reconstruction or neobladder can be derived from various segments of the intestine to create a low – pressure reservoir. An isolated segment of the distal ileum is often preferred
Page 65
Page 66
Cystectomy - complications
• Ileus• Wound infection• Sepsis• Pelvic abscess• Hemorrhage• Wound dehiscence• Bowel obstruction• Enterocutaneous fistula• Rectal injury
Page 67
Urinary diversion-complications
• Complications of urinary diversion include the following:• Hyperchloremic metabolic acidosis - If the ileum or
colon is used• Urinary tract infections (UTIs)• Stomal-peristomal inflammation, hernia, or stenosis• Urinary calculi• Vitamin B-12 deficiency - For diversions affecting the
terminal ileum• Ureterointestinal stenosis leading to hydronephrosis
Page 68
Radiation therapy
• Radiation treatment for bladder cancer uses high-energy X-rays to kill cancer cells and shrink tumors. It may be given after surgery. It may be used along with chemotherapy. Sometimes it is used instead of surgery or chemotherapy.
• External beam radiation comes from a machine outside the body. The machine aims radiation at the area where the cancer cells are found.
• Internal radiation uses needles, seeds, wires, or catheters that contain radioactive materials placed close to or directly into the bladder.
Page 69
Intravesical therapy
• It is the instillation of immune stimulating agent into the bladder by urethral catheter. Usually BCG is used. It stimulates the immune system rather than directly act on the cancer cells in the bladder. If BCG fais, alpha interferon , valrubicin etc are used.
Page 70
Chemtherapy
• Antineoplastics, Antimetabolite• These agents inhibit cell growth and proliferation. They interfere
with DNA synthesis by blocking the methylation of deoxyuridylic acid.
• Fluorouracil (Adrucil)• • Methotrexate (Trexall, Rheumatrex)• • Gemcitabine (Gemzar)• • Pemetrexed (Alimta)•
Page 71
Antineoplastics, Vinca Alkaloid
• Vinca alkaloids act on the G and S phases of mitosis, inhibiting microtubule formation and inhibiting DNA/RNA synthesis.
• Vinblastine (Velban)
Page 72
Antineoplastics, Anthracycline
• Anthracycline antineoplastics inhibit DNA and RNA synthesis by steric obstruction. They intercalate between DNA base pairs and trigger DNA cleavage by topoisomerase II.
• Doxorubicin (Adriamycin, Caelyx, Rubex)
Page 73
• Valrubicin (Valstar) :It is indicated for intravesicular treatment of bladder carcinoma in situ (CIS) that is refractory to treatment with bacillus Calmette-Guérin (BCG).
• Antineoplastics, Alkylating• Cisplatin• Carboplatin (Paraplatin)• • Ifosfamide (Ifex)• • Thiotepa (Thioplex, TSPA)
Page 74
• Antineoplastics, Antimicrotubular• These agents prevent cell growth and
proliferation. They work by enhancing tubulin dimers, as well as by stabilizing existing microtubules and inhibiting their disassembly.
• Docetaxel (Taxotere, Docefrez)
Page 75
• Chemotherapy – First Line • - Gemcitabine – Cisplatin • - Intensified MVAC Dose-intense MVAC +
GCSF • - Carboplatin – Gemcitabine • Chemotherapy – Second Line • - Paclitaxel – Carboplatin • - Docetaxel • - Ifosphamide
Page 76
• Neoadjuvant chemotherapy • Indications for Neoadjuvant Chemotherapy • 1. Clinical stage T2 – T4a • 2. No nodal or metastatic disease • 3. Urothelial histology only • 4. Candidate for radical cystectomy • Regimens: • To receive 3-4 cycles • Possible (not evaluated in RCT): • 1. Gemcitabine + cisplatin/carboplatin • 2. Dose-intense MVAC
Page 77
Chemotherapeutic Regimens for Metastatic Bladder Cancer
• First-line, platinum-based combinations are active in locally advanced and metastatic urothelial carcinoma.
• Methotrexate, vinblastine, doxorubicin (Adriamycin), and cisplatin (MVAC) is a standard combination regimen for treatment of metastatic bladder cancer
• Gemcitabine and cisplatin (GC) is a newer regimen that has been shown to be as effective as MVAC but with less toxicity. GC is now considered a first-line treatment for bladder cancer
Page 78
Nursing management
• preoperative period Assessment• Nutritional assessment • Advise tobacco cessation • Assessment of activities of daily living functional status • Determination of eligibility for financial support • Inclusion of partner/family members to establish support mechanism • Psychological assessment • Provision of audio and visual information • Provision of opportunity to meet similar patients • Addressing religious and cultural issues • Implementation of care plans• Cardiopulmonary assessment • Learning needs
Page 79
• Nursing diagnoses• Anxiety related to surgical procedure• Deficient knowledge about the surgical
procedure and postoperative care
Page 80
Post operative
• Nursing diagnoses• Risk for impaired skin integrity related to problems
in managing the urin collection appliance• Acute pain related to surgical incision• Disturbed body image related to urinary diversion• Potential sexual dysfunction related to structural
and physiologic alterations• Deficient knowledge about the management of
urinary function.
Page 81
Interventions in post op period
• In the post operative period , urine volumes are monitored hourly. Through out the patient’s hospitalization, the nurse monitors closely for complications.
• A urine output below 3oml/h may indicate dehydration or an obstruction in the ileal conduit, with possible backflow or leakage from the ureterileal anastomosis. Hematuria may be noted in the first 48 hrs after the surgery.if the ureteral stents are not draining , the nurse may be instructed to carefully irrigate with 5-10 ml sterile normal saline solution.
Page 82
• Providing stoma and skin care • Encouraging fluids and relieving
anxiety• Promoting home care
– Teaching patient self care– Changing the appliance – Controlling odor– Managing ostomy appliance– Contining care
Page 83
Thank
you